News & Events

GeneCentric Announces “Advances in RNA-based Biomarker Development for Precision Oncology” Webinar Series

This three-part webinar series, “Advances in RNA-based Biomarker Development for Precision Oncology”, will highlight trends in RNA-based biomarker development for precision oncology, ranging from the use of gene expression signatures in the development cancer therapies, to the development of RNA-based companion diagnostics, to novel applications for RNA-based biomarkers in cancer treatment. Part 1 is August 24th, with Parts 2 and 3 September 10th and October 8th.

GeneCentric Therapeutics Enters into Research Collaboration with Janssen on Genomic Drug Response Biomarkers for Non-Muscle Invasive Bladder Cancer

RNA-based investigation builds on prior bladder cancer research Durham, NC, August 12, 2020 – GeneCentric Therapeutics today announced it has entered into a research collaboration with Janssen Research & Development, LLC (Janssen) around RNA-based drug response biomarkers for non-muscle invasive bladder cancer (NMIBC). The research will involve the application of GeneCentric’s advanced RNA-based molecular profiling platform […]

GeneCentric Therapeutics and Erasmus University Medical Center Enter Bladder Cancer Research Collaboration

Research to focus on potential biomarkers of disease progression, immune and treatment response in the setting of Non-Muscle Invasive Bladder Cancer DURHAM, N.C., USA and ROTTERDAM, THE NETHERLANDS, August 5, 2020 — GeneCentric Therapeutics, Inc. and Erasmus University Medical Center (EUMC) today announced that they have entered into a research collaboration to identify RNA-based drug […]

Pancreatic Cancer Action Network and GeneCentric Therapeutics Launch Partnership in Pancreatic Cancer Research

Collaboration will focus on applying advanced RNA-based molecular technologies to predict disease progression and identify potential drug response biomarkers MANHATTAN BEACH, CA and DURHAM, N.C., July 29, 2020 — The Pancreatic Cancer Action Network (PanCAN) and GeneCentric Therapeutics, Inc. today announced that they have entered into a collaborative research partnership for the advancement of RNA-based […]

GeneCentric has moved its offices

GeneCentric Therapeutics is now located at 100 Capitola Dr, Suite275 Durham, NC 27713

Covid-19 Status

GeneCentric Therapeutics continues to monitor the evolving novel Coronavirus (COVID-19) situation closely. We are following the Centers for Disease Control and Prevention (CDC) recommendations on prevention and spread of the virus along with specific guidance for travelers. Currently, the company doesn’t anticipate any changes with its current client projects and will continuously update clients.